Cic edizioni internazionali
Clinical Cases in mineral and bone metabolism

Low-dose diclofenac in patients with fragility fractures

Original Article, 15 - 17
doi: 10.11138/ccmbm/2017.14.1.015
Tag this article
Abstract
Enhanced HTML Full text PDF
Most osteoporotic patients complain of back pain one year after a fragility vertebral fracture and the frequency of chronic back pain increases with increasing age. The use of the lowest effective dose of an analgesic which is able to control symptoms seems to be a possible solution in order to limit potential side effects in multi-treated elderly patients. Non-steroidal anti-inflammatory drugs (NSAIDs) have a proven efficacy in the treatment of back pain associated with fragility vertebral fractures and diclofenac is available at low-dose subcutaneous injective formulation. This is the rational of ImPAVeDic study, acronym of Improvement of back Pain Associated with fragility Vertebral fractures with low-dose Diclofenac, an observational study that will be performed in a group of 50 elderly (≥ 65 years), male and female osteoporotic patients with symptomatic fragility vertebral fractures. The objective of the study is to evaluate the improvement of back pain in the study population treated with low-dose diclofenac and regularly monitored for 2-6 months. Visual Analogic Scale (VAS) and Numerical Rating Scale (NRS) will be used for pain monitoring. The reduction of the risk of occurrence of drug side effects can favour the optimization of elderly patients’ care.

Vol. XIV (No. 1) 2017 January - April

  1. From the Editor-in-Chief
    Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.011
  2. Low-dose diclofenac in patients with fragility fractures
    Vannucci L., Fossi C., Gronchi G., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.015
  3. Vitamin D levels and their impact on mineral metabolism in HIV infected patients: an exploratory study
    Mastaglia S., Watson D., Bello N., Fridman V., Stecher D., Oliveri B.
    doi: 10.11138/ccmbm/2017.14.1.018
  4. New quantitative ultrasound techniques for bone analysis at the distal radius in hip fracture cases: differences between femoral neck and trochanteric fractures
    Horii M., Fujiwara H., Sakai R., Sawada K., Mikami Y, Toyama S., Ozaki E., Kuriyama N., Kurokawa M., Kubo T.
    doi: 10.11138/ccmbm/2017.14.1.023
  5. Use of teriparatide off-label: our experience and review of literature
    Ciurlia E., Tranquilli Leali P., Doria C.
    doi: 10.11138/ccmbm/2017.14.1.028
  6. The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer
    Demirtas D., Bilir C., Demirtas A.O., Engin H.
    doi: 10.11138/ccmbm/2017.14.1.035
  7. A comparison of two fixation methods for femoral trochanteric fractures: a new generation intramedullary system vs sliding hip screw
    Carulli C., Piacentini F., Paoli T., Civinini R., Innocenti M.
    doi: 10.11138/ccmbm/2017.14.1.041
  8. The use of cholecalciferol in patients with hip fracture
    Cianferotti L., Parri S., Gronchi G., Civinini R., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.048
  9. Evaluation of bone microstructure in CRPS-affected upper limbs by HR-pQCT
    Mussawy H., Schmidt T., Rolvien T., Rüther W., Amling M.
    doi: 10.11138/ccmbm/2017.14.1.054
  10. Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update
    Marini F., Cianferotti L., Giusti F., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.060
  11. Bone health in menopausal women: a role for General Practitioners
    Michieli R., Musto M.
    doi: 10.11138/ccmbm/2017.14.1.071
  12. Legg-Calvé-Perthes disease: classifications and prognostic factors
    Rampal V., Clément J.-L., Solla F.
    doi: 10.11138/ccmbm/2017.14.1.074
  13. Transient osteoporosis of the hip with a contralateral delayed involvement: a case report
    Iannò B., De Gori M., Familiari F., Pugliese T., Gasparini G.
    doi: 10.11138/ccmbm/2017.14.1.083
  14. A case report: hypercalcemia due to vitamin supplementation in a patient with neurofibromatosis
    Crone M., Fogarty K.
    doi: 10.11138/ccmbm/2017.14.1.087
  15. Is this a seizure?
    Franceschet G., Mazzucato M., Censi S., Simmini S., Boscaro M., Camozzi V.
    doi: 10.11138/ccmbm/2017.14.1.089
  16. Histological and micro Computed Tomography analysis of a femoral stress fracture associated with prolonged bisphosphonate use
    Somford M.P., van Ruijven L.J., Kloen P., Bakker A.D.
    doi: 10.11138/ccmbm/2017.14.1.092
  17. Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider?
    De Keukeleire S., Muylle K., Tsoumalis G., Vermeulen S., Vogelaers D.
    doi: 10.11138/ccmbm/2017.14.1.097
  18. Acute severe diarrhoea and hyponatremia after zoledronic acid infusion: an acute phase reaction
    Shafi Kuchay M., Farooqui K.J., Mithal A.
    doi: 10.11138/ccmbm/2017.14.1.101
  19. LoCa LoPa myelopathy: is prevention better than cure?
    Pandita K.K., Razdan S., Pandita S.
    doi: 10.11138/ccmbm/2017.14.1.105
Last Viewed articles: la lista degli ultimi x visitati.
  1. Low-dose diclofenac in patients with fragility fractures
    Vannucci L., Fossi C., Gronchi G., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.015
credits